Ampel BioSolutions, LLC   Report issue

For profit Phase 2 Phase 4
Founded: Charlottesville VA United States (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2015
NCT02598596
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Ampel BioSolutions, LLC

Active Ingredients

Drugs in Phase 4 Trials (1)

prednisone (meticorten) (1 trial)

Drugs in Phase 2 Trials (1)

pegloticase (krystexxa) (1 trial)

Drugs in Other Trials (1)

krill oil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatigue (Phase 4)

Lupus Erythematosus, Systemic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3